Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: empagliflozin
Drug: semaglutide

First Posted Date: 2016-08-11

Last Posted Date: 2022-07-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 822

Registration Number: NCT02863328

Locations: 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: sitagliptin
Drug: semaglutide

First Posted Date: 2016-07-29

Last Posted Date: 2022-07-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 504

Registration Number: NCT02849080

Locations: 🇹🇷
Novo Nordisk Investigational Site, Rize, Turkey

A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: SNAC
Drug: Microgynon®

First Posted Date: 2016-07-27

Last Posted Date: 2017-06-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 25

Registration Number: NCT02845219

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: insulin degludec/insulin aspart

First Posted Date: 2016-07-26

Last Posted Date: 2020-02-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT02844790

Locations: 🇨🇳
Novo Nordisk Investigational Site, Beijing, China

A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: placebo
Drug: NNC9204-0530

First Posted Date: 2016-07-18

Last Posted Date: 2018-01-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT02835235

Locations: 🇺🇸
Novo Nordisk Investigational Site, Lincoln, Nebraska, United States

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: semaglutide

First Posted Date: 2016-07-11

Last Posted Date: 2020-02-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 324

Registration Number: NCT02827708

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2016-07-07

Last Posted Date: 2019-11-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 472

Registration Number: NCT02825251

Locations: 🇬🇧
Novo Nordisk Investigational Site, St Helens, United Kingdom

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®

Completed

Conditions: Diabetes

Interventions: Drug: insulin degludec/insulin aspart

First Posted Date: 2016-07-01

Last Posted Date: 2019-10-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1355

Registration Number: NCT02821052

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea

Completed

Conditions: Diabetes

Interventions: Drug: insulin degludec

First Posted Date: 2016-05-20

Last Posted Date: 2020-04-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3303

Registration Number: NCT02779413

Locations: 🇰🇷
Novo Nordisk Investigational Site, Wonju, Korea, Republic of

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: semaglutide

First Posted Date: 2016-05-16

Last Posted Date: 2020-12-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 15

Registration Number: NCT02773381

Locations: 🇬🇧
Novo Nordisk Investigational Site, Leeds, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy